CVRx, Inc. (NASDAQ:CVRX) Receives $14.00 Average Price Target from Brokerages

Key Points

• CVRx, Inc. has received a consensus rating of "Moderate Buy" from seven brokerages, with one sell rating, five buy ratings, and one strong buy rating.
• The average 12-month target price for CVRx shares is $14.00, while current trading is around $7.87.
• The company's quarterly earnings report revealed a loss of ($0.57) EPS, slightly worse than analyst estimates, with revenues beating expectations at $13.59 million.

CVRx, Inc. (NASDAQ:CVRX - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $14.00.

Several equities analysts have recently commented on the stock. William Blair raised shares of CVRx to a "strong-buy" rating in a research note on Monday, July 7th. Cantor Fitzgerald restated an "overweight" rating and issued a $11.00 price objective on shares of CVRx in a report on Tuesday, August 5th.

Institutional Investors Weigh In On CVRx

Institutional investors have recently made changes to their positions in the company. Principal Financial Group Inc. purchased a new stake in shares of CVRx during the first quarter valued at approximately $731,000. Bank of America Corp DE grew its holdings in shares of CVRx by 13.9% during the fourth quarter. Bank of America Corp DE now owns 103,207 shares of the company's stock valued at $1,308,000 after buying an additional 12,600 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of CVRx by 1,469.3% during the first quarter. GAMMA Investing LLC now owns 4,598 shares of the company's stock valued at $56,000 after buying an additional 4,305 shares during the last quarter. Northern Trust Corp boosted its holdings in CVRx by 4.3% in the fourth quarter. Northern Trust Corp now owns 138,883 shares of the company's stock worth $1,760,000 after purchasing an additional 5,671 shares during the last quarter. Finally, Two Sigma Investments LP boosted its holdings in CVRx by 80.7% in the fourth quarter. Two Sigma Investments LP now owns 55,367 shares of the company's stock worth $702,000 after purchasing an additional 24,734 shares during the last quarter. Hedge funds and other institutional investors own 75.27% of the company's stock.

CVRx Trading Down 12.1%

NASDAQ CVRX traded down $0.95 during trading on Friday, hitting $6.92. 290,919 shares of the company's stock traded hands, compared to its average volume of 166,110. The stock has a fifty day moving average of $7.64 and a two-hundred day moving average of $7.88. The company has a debt-to-equity ratio of 0.85, a current ratio of 11.99 and a quick ratio of 10.78. CVRx has a 12-month low of $4.30 and a 12-month high of $18.55. The firm has a market cap of $180.96 million, a P/E ratio of -3.30 and a beta of 1.26.

CVRx (NASDAQ:CVRX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.05). The business had revenue of $13.59 million for the quarter, compared to analysts' expectations of $13.22 million. CVRx had a negative net margin of 95.61% and a negative return on equity of 79.31%. CVRx has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, sell-side analysts expect that CVRx will post -1.91 EPS for the current year.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.